Overview

Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

Status:
Completed
Trial end date:
2021-03-13
Target enrollment:
Participant gender:
Summary
This 4-week study will evaluate the safety, tolerability and preliminary evidence of efficacy of evenamide (7.5,and 15 mg and placebo, bid) treatment in outpatients with chronic schizophrenia.
Phase:
Phase 2
Details
Lead Sponsor:
Newron Pharmaceuticals SPA